[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

Date publication

juillet 2012

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier , Pr BORG Christophe , Pr PIVOT Xavier , Dr MANSI Laura , Dr THIERY-VUILLEMIN Antoine , Dr KIM Stephano , Pr KLEINCLAUSS François

Tous les auteurs :
Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/22516539

Résumé

Castration resistant prostate cancer occurs when patients experience disease progression despite appropriate hormonal manipulations. In these patients, chemotherapy remains standard treatment. Preclinical and clinical data have demonstrated the potential utility of an immunotherapy-based approach for the treatment of prostate cancer (PC). The phase III trial (IMPACT) has recently reported an advantage for Sipuleucel-T over placebo, with an overall survival 4.1 months superior to placebo. Sipuleucel-T is also the first FDA-approved immunotherapy for prostate cancer. These promising results need to be confirmed with other large studies and within previous step of PC. Neoplasic cells can escape immune responses by multiple mechanisms. A better knowledge of these mechanisms is of major concern for the future development of new immunotherapies approach.

Référence

Bull Cancer. 2012 Jul;99 Suppl 1:S57-65